Applications published 27 May 2009

Granulate containing a pharmaceutically active substance and an emulsifier and method for its manufacture
Echo Pharmaceuticals 2061427*

Improvements in pharmaceutical compsns
York Pharma 2061428*

Method of treating bone cancer
ED Geistlich Soehne AG fuer Chemische Industrie 2061429*

• Bis (thiohydrazide amides) formulation
Synta Pharmaceuticals 2061430*

• Enhanced immediate release formulations of topiramate
Supernus Pharmaceuticals 2061431*

• Nano-vehicle for the transcutaneous transport, preparation containing the same and its use
Barnikol-Keuten, Doris 2061432*

• Compsns and methods for enhancing transport through mucus
Johns Hopkins University 2061433*

• Engineering shape of polymeric micro- and nanoparticles
The Regent of the University of California 2061434*

• Polystyrene sulphonate polymer tablets, their preparation and use
Genzyme 2061435*

• Ibuprofen-effervescent preparation having a high dissolution rate and method for the production thereof
Losan Pharma 2061436*

• Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and HMG-CoA reductase inhibitors
Hanall Pharmaceutical 2061437*

• Extended release gastro-retentive oral drug delivery system for valsartan
Novartis 2061438*

• Pharmaceutical compsn comprising a plurality of mini-tablets comprising a factor XA inhibitor
Glaxo Group 2061439*

• A pharmaceutical compsn of tacrolimus
Sigmoid pharma 2061440*

• Transdermal delivery of meptazinol
Shire Pharmaceuticals 2061441*

• Treatment, prevention and reversal of alcohol-induced brain disease
Rhode Island Hospital 2061442*

• Polyconjugates for in vivo delivery of polynucleotides
F Hoffmann-La Roche 2061443*

• Compsns and methods for treating, controlling, reducing, ameliorating or preventing allergies
Bausch & Lomb 2061444*

• Antimicrobial compsns
Research Foundation of the City University of New York; Pace University; Long Island University 2061445*

• Use of CDK inhibitors for the treatment of granulocyte mediated disorders
University Court of the University of Edinburgh 2061446*

• Sustained release formulation of naltrexone
Orexigen Therapeutics 2061447*

• Substituted acetylenic compounds useful for the treatment of diseases
Leo Pharma 2061449*

• Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
MCW Research Foundation 2061450*

• Bis(thiohydrazide amides) for treating melanoma
Synta Pharmaceuticals 2061451*

• Anti-cancer use of caffeic acid and derivatives
Piramal Life Sciences 2061452*

• 2,5-dihydroxybenzene compounds for treating cancers and haematological dyscrasias
Action Medicines 2061453*

• Compsns and methods for inhibiting cytochrome P450
Sequoia Pharmaceuticals 2061456*

• Novel nutraceutical and pharmaceutical compsns and use thereof for the treatment, co-treatment or prevention of cartilage degradation or cartilage damage in joints
DSM 2061457*

• Topiramate compsns and methods for their use
Regents of the University of Minnesota 2061458*

• 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
Intellect Neurosciences 2061459*

• 2-aminobenzoxazole carboxamides as 5HT3 modulators
Albany Molecular Research 2061460*

• 3-azabicyclo[4.1.0]heptane derivatives for the treatment of depression
Glaxo Group 2061461*

• Treating pain, diabetes and lipid metabolism disorders
Schering 2061462*

• Topical compsn comprising a dihydropyridine calcium antagonist
Moberg Derma 2061463*

• Compsn therapy for tumoral disease treatment
Ramot at Tel Aviv University 2061464*

• Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
Valeant Pharmaceuticals 2061465*

• 4-thio substituted quinoline and naphthyridine compounds
Xtl Biopharmaceuticals 2061466*

• Tyrosine kinase inhibitors containing a zinc binding moiety
Curis 2061468*

• Quinazoline based EGFR inhibitors containing a zinc binding moiety
Curis 2061469*

• Haloalkyl-substituted pyrimidinone derivatives
Neurogen 2061470*

• Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
The Governors of the University of Alberta 2061471*

• Bacterial thioredoxin reductase inhibitors and methods for use thereof
Thioredoxin Systems; Thyogen Pharmaceuticals 2061472*

• Increasing ATP availability by inhibition of creatine kinase (CK) leakage resulting from high-intensity exercise
Aplodan Formulations 2061473*

• Solid citrate and tartrate salts of DPP-IV inhibitors
Phenomix 2061474*

• Antisense compsn and method for inhibition of MIRNA biogenesis
AVI BioPharma 2061475*

• Compsns containing CDP-choline and methods of use thereof
Massachusetts Institute of Technology 2061461*

• Compsns and methods for detection of lyosomal storage disease
Genzyme 2061462*

• Sperm cell separation methods and compsns containing aptamers or nucleic acid sequences for use therein
Biocern 2061463*

• Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
Bipar Services 2061479*

• GLMS riboswitches, structure-based compound design with GLMS riboswitches, and methods and compsns sue of and with GLMS riboswitches
Yale University 2061480*

• Cationic latex as carrier for bioactive ingredients and methods for making and using the same
Mallard Creek Polymers 2061481*

• Method of modulation of expression of epidermal growth factor receptor (EGFR) involving MIRNA
The University of Western Australia 2061482*

• Oral polymeric membrane feruloyl esterase producing bacteria formulation
McGill University 2061483*

• Treatment, prevention and reversal of alcohol-induced liver disease
Rhode Island Hospital 2061484*

• Method of treating peripheral nerve disorders
Varleigh 2061485*

• Methods and compsns for sealing and adhering biological tissues and medical uses thereof
Southeastern Medical Technologies 2061486*

• Modifications of cupredoxin derived peptides and methods of use thereof
The Board of Trustees of the University of Illinois 2061487*

• Selectively targeted antimicrobial peptides and the use thereof
The Regents of the University of California 2061488*

• High affinity EPHB receptor binding compounds and methods of use thereof
The Burnham Institute 2061489*

• Modulators of Candida hyphal morphogenesis and uses thereof
Agency for Science, Technology and Research 2061490*

• Methods and compsns for conserving and/or preparing an organ or tissue for transplant
Regenrx Biopharmaceuticals 2061491*

• Method of ameliorating pain by modification of NMDA receptors through inhibition of SRC
The Hospital for Sick Children 2061492*

• Compsns to reduce or prevent skin cancer
Essential Skincare 2061493*

• Regulation of expression of P140cap protein in tumours
Universita" Degli Studi di Torino 2061494*

• WNT antagonists and their use in the diagnosis and treatment of WNT-mediated disorders
Genentech 2061495*

• Methods of using IL-31 to treat airway hyper-responsiveness and asthma
Zymogenetics 2061496*

• Compsns and methods for treatment of chronic fatigue syndrome and neurodegenrative diseases
Mondobiotech Laboratories 2061497*

• Compsns and methods to prevent cancer with cupredoxins
The Board of Trustees of the University of Illinois 2061498*

• Novel nematode protein and its use in producing anthelminthis agents and vaccines
Moredun Research Institute 2061499*

• Pharmaceutical and sunscreen compsns comprising caspase-14
VIB 2061500*

• Method of treating respiratory disorders
Varleigh 2061501*

• Carbohydrate-based vaccines for HLV
Duke University 2061502*

• Cytogenic T-lymphocyte-inducing immunogens for prevention, treatment and diagnosis of cancer
Immunotope 2061503*

• Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies
The Johns Hopkins University 2061504*

• Compsn for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
BT Pharma 2061505*